Shopping Cart 0
Cart Subtotal
USD 0

Hemispherx Biopharma Inc (HEB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Hemispherx Biopharma Inc (Hemispherx) is a biopharmaceutical company, which develops, manufactures and commercializes drug therapies for the treatments of viral and immune based chronic disorders. It offers products for the treatment of various diseases such as hepatitis B, hepatitis C, chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME), kidney cancer and metastatic malignant melanoma; multiple sclerosis, hepatitis C, HIV, west Nile virus, and SARS; and Alferon LDO (Low Dose Oral), an oral form of Alferon N Injection for influenza viruses. The company operates production facility in New Brunswick, New Jersey. Hemispherx is headquartered in Orlando, Florida, the US.

Hemispherx Biopharma Inc (HEB)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 6

Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Hemispherx Biopharma Inc, Medical Devices Deals, 2012 to YTD 2018 11

Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deal Details 14

Partnerships 14

Hemispherx Biopharma Enters into Clinical Trial Agreement with Roswell Park 14

Hemispherx Biopharma and Roswell Park Enter into Collaboration Agreement 15

Hemispherx Biopharma Enters into Agreement with University of Nebraska Medical 16

Hemispherx Biopharma Enters into Distribution Agreement with GP Pharm for Ampligen 17

Scientific Products Pharma Enters into Agreement with Hemispherx Biopharma 18

myTomorrows Enters into Agreement with Hemispherx Biopharma 19

Hemispherx Biopharma Amends Agreement with myTomorrows 20

Licensing Agreements 21

Hemispherx Biopharma Enters into Licensing Agreement with Emerge Health 21

Hemispherx Biopharma Enters into Licensing Agreement with Emerge Health 22

Equity Offering 23

Hemispherx Biopharma Plans to Raise up to USD75 Million in Public Offering of Securities 23

Hemispherx Biopharma to Raise USD2.6 Million in Private Placement of Shares 24

Hemispherx Biopharma to Raise USD0.5 Million in Private Placement of Shares 25

Hemispherx Biopharma Plans to Raise USD1.6 Million in Public Offering of Shares 26

Hemispherx Biopharma Plans to Raise Funds through Private Placement of Shares, upon Exercise of Warrants 27

Hemispherx Biopharma to Raise up to USD1 Million in Private Placement of Shares 28

Hemispherx Biopharma Raises USD0.05 Million in Private Placement of Shares 29

Hemispherx Biopharma Raises USD5 Million in Private Placement of Shares 30

Hemispherx Biopharma to Raise up to USD8 Million in Public Offering of Shares 31

Hemispherx Biopharma Announces Public Offering Of Shares For Up To USD 75 Million 33

Hemispherx Biopharma Inc-Key Competitors 34

Hemispherx Biopharma Inc-Key Employees 35

Hemispherx Biopharma Inc-Locations And Subsidiaries 36

Head Office 36

Other Locations & Subsidiaries 36

Recent Developments 37

Financial Announcements 37

Aug 15, 2018: Hemispherx announces six months ended June 30, 2018 financial results 37

May 16, 2018: Hemispherx Biopharma Reports First Quarter 2018 Financial Results and Provides Business Update 38

Apr 02, 2018: Hemispherx Biopharma Announced Financial Results for the Year Ended December 31, 2017 39

Nov 15, 2017: Hemispherx Biopharma Announces Corporate Progress and Financial Results for the Nine Months Ended September 30, 2017 40

Aug 15, 2017: Hemispherx Biopharma Announces Corporate Progress and Financial Results for the Six Months Ended June 30, 2017 41

May 15, 2017: Hemispherx Biopharma Q1 net loss increases 42

Mar 31, 2017: Hemispherx Biopharma Announces Financial Results for the Year Ended December 31, 2016 43

Corporate Communications 44

May 31, 2017: Hemispherx Biopharma appoints new deputy chief medical officer 44

Product News 45

12/20/2017: Hemispherx Successfully Completes Commercial Scale Demonstration Batch of Ampligen at Contract Manufacturer 45

09/18/2018: Hemispherx to Distribute Second Lot of Ampligen for use in Multiple Indications in Argentina, the United States and Europe 46

08/28/2018: Hemispherx Releases Recently Manufactured Ampligen for Pancreatic Cancer Early Access Program in the Netherlands to Fill Stock Order 47

08/24/2018: Hemispherx to present at the 20th annual Rodman & Renshaw Global Investment Conference 48

08/08/2017: Hemispherx Biopharma Announces Collaboration with Millions Missing Canada to Bring Medication to Canadians for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome 49

07/03/2018: Hemispherx Notes the Importance of Immunizations During Upcoming National Immunization Awareness Month and Potential of Ampligen in Influenza Vaccine Strategies 50

06/15/2018: Hemispherx Releases First 8,500 Vial Lot of Ampligen to Supply Expanded Access Programs in the United States, Europe and Canada for ME/CFS and Pancreatic Cancer and Announces Successful Finish of Second Commercial Size Lot 51

06/05/2018: Hemispherx Announces New Data Showing Ampligen's Positive Role in Reprograming Tumor Microenvironment 52

05/31/2018: Hemispherx Biopharma and Roswell Park Plan Phase I/II Study of Ampligen Plus Checkpoint Inhibitors 53

05/31/2017: Hemispherx Biopharma Enhances Ampligen Manufacturing and Scientific Capabilities 54

05/31/2017: Hemispherx Biopharma Repurposes Ampligen in Immuno-Oncology 55

05/15/2017: Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2017 56

04/17/2018: Hemispherx Successfully Completes Production of More Than 8,500 Vials of Ampligen for Commercial Sales and Expanded Clinical Programs 57

04/04/2018: Hemispherx Expands Ampligen Early Access Programme to Canada to Treat ME/CFS Patients 58

03/06/2017: Hemispherx Biopharma Meets Ampligen Sales Milestone in the 1st Quarter of 2017 59

03/05/2018: Hemispherx to Present Alferon N Injection at the 30th Annual ROTH Conference 60

03/05/2018: Hemispherx to Present Ampligen at the 30th Annual ROTH Conference 61

02/26/2018: Hemispherx To Supply Ampligen for Pancreatic Cancer Patients in Canada Under Special Access Program 62

01/26/2018: Hemispherx Announces Presentation on the Potential Role of Ampligen as an Immune System Amplifier Improving Seasonal Flu Vaccine Cross-Protection 63

01/26/2017: Hemispherx Announces First Shipment of Newly Manufactured Rintatolimod (Ampligen) for Sale to Early Access Program in Europe 64

01/25/2018: Hemispherx Announces Data Presentation on the Potential for Ampligen to Improve Cancer Outcomes with Checkpoint Inhibitors 65

01/23/2018: Hemispherx Comments on USD 500+ Million Market Opportunity for Ampligen, the Only Late Stage ME/CFS Candidate in the U.S. 66

01/17/2018: Hemispherx Enters into Sale/Leaseback Agreement for NJ Development and Production Facility 67

01/11/2018: Hemispherx Enhances Manufacturing Efficiency of Ampligen 68

01/11/2017: Hemispherx Biopharma Announces Extension of Rintatolimod European Early Access Program (EAP) to Pancreatic Cancer Patients 69

Product Approvals 70

Jun 27, 2018: Hemispherx Opens FDA-Approved Reimbursement Based Expanded Access Treatment Program for ME/CFS to New Enrollees at Approved Clinical Sites in Nevada and North Carolina 70

Clinical Trials 71

Jul 09, 2018: Hemispherx Files Positive Safety Report on Intranasal Use of Ampligen in Combination with FluMist Influenza Vaccine 71

Jan 31, 2018: Hemispherx's Ampligen Highlighted in Review of Role of TLR3 Agonist Support for Universal Flu Immunization Development Programs 72

Jan 09, 2018: Hemispherx Announces Presentation of New-Found Properties of Ampligen at Immuno-Oncology Frontiers Conference 73

Aug 14, 2017: Hemispherx Human Safety Study of Intranasal Ampligen with Influenza Vaccine Shows Ampligen was Generally Well-Tolerated 74

Jul 10, 2017: Hemispherx Updates Status of Immuno-Oncology Program in Pancreatic Cancer 75

Other Significant Developments 76

Dec 19, 2017: Hemispherx Highlights Year-To-Date Progress, Outlines Key Objectives 76

Appendix 78

Methodology 78

About GlobalData 78

Contact Us 78

Disclaimer 78


List Of Figure

List of Figures

Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Hemispherx Biopharma Inc, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Hemispherx Biopharma Inc, Deals By Therapy Area, 2012 to YTD 2018 10

Hemispherx Biopharma Inc, Medical Devices Deals, 2012 to YTD 2018 11

Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Hemispherx Biopharma Enters into Clinical Trial Agreement with Roswell Park 14

Hemispherx Biopharma and Roswell Park Enter into Collaboration Agreement 15

Hemispherx Biopharma Enters into Agreement with University of Nebraska Medical 16

Hemispherx Biopharma Enters into Distribution Agreement with GP Pharm for Ampligen 17

Scientific Products Pharma Enters into Agreement with Hemispherx Biopharma 18

myTomorrows Enters into Agreement with Hemispherx Biopharma 19

Hemispherx Biopharma Amends Agreement with myTomorrows 20

Hemispherx Biopharma Enters into Licensing Agreement with Emerge Health 21

Hemispherx Biopharma Enters into Licensing Agreement with Emerge Health 22

Hemispherx Biopharma Plans to Raise up to USD75 Million in Public Offering of Securities 23

Hemispherx Biopharma to Raise USD2.6 Million in Private Placement of Shares 24

Hemispherx Biopharma to Raise USD0.5 Million in Private Placement of Shares 25

Hemispherx Biopharma Plans to Raise USD1.6 Million in Public Offering of Shares 26

Hemispherx Biopharma Plans to Raise Funds through Private Placement of Shares, upon Exercise of Warrants 27

Hemispherx Biopharma to Raise up to USD1 Million in Private Placement of Shares 28

Hemispherx Biopharma Raises USD0.05 Million in Private Placement of Shares 29

Hemispherx Biopharma Raises USD5 Million in Private Placement of Shares 30

Hemispherx Biopharma to Raise up to USD8 Million in Public Offering of Shares 31

Hemispherx Biopharma Announces Public Offering Of Shares For Up To USD 75 Million 33

Hemispherx Biopharma Inc, Key Competitors 34

Hemispherx Biopharma Inc, Key Employees 35

Hemispherx Biopharma Inc, Other Locations 36

Hemispherx Biopharma Inc, Subsidiaries 36

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Hemispherx Biopharma Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Hemispherx Biopharma Inc (Hemispherx) is a biopharmaceutical company, which develops, manufactures and commercializes drug therapies for the treatments of viral and immune based chronic disorders. It offers products for the treatment of various diseases such as hepatitis B, hepatitis C, chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME), kidney cancer and metastatic malignant melanoma; multiple sclerosis, hepatitis C, HIV, west Nile virus, and SARS; and Alferon LDO (Low Dose Oral), an oral form of Alferon N Injection for influenza viruses. The company operates production facility in New Brunswick, New Jersey. Hemispherx is headquartered in Orlando, Florida, the US.

Hemispherx Biopharma Inc (HEB)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 6

Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Hemispherx Biopharma Inc, Medical Devices Deals, 2012 to YTD 2018 11

Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deal Details 14

Partnerships 14

Hemispherx Biopharma Enters into Clinical Trial Agreement with Roswell Park 14

Hemispherx Biopharma and Roswell Park Enter into Collaboration Agreement 15

Hemispherx Biopharma Enters into Agreement with University of Nebraska Medical 16

Hemispherx Biopharma Enters into Distribution Agreement with GP Pharm for Ampligen 17

Scientific Products Pharma Enters into Agreement with Hemispherx Biopharma 18

myTomorrows Enters into Agreement with Hemispherx Biopharma 19

Hemispherx Biopharma Amends Agreement with myTomorrows 20

Licensing Agreements 21

Hemispherx Biopharma Enters into Licensing Agreement with Emerge Health 21

Hemispherx Biopharma Enters into Licensing Agreement with Emerge Health 22

Equity Offering 23

Hemispherx Biopharma Plans to Raise up to USD75 Million in Public Offering of Securities 23

Hemispherx Biopharma to Raise USD2.6 Million in Private Placement of Shares 24

Hemispherx Biopharma to Raise USD0.5 Million in Private Placement of Shares 25

Hemispherx Biopharma Plans to Raise USD1.6 Million in Public Offering of Shares 26

Hemispherx Biopharma Plans to Raise Funds through Private Placement of Shares, upon Exercise of Warrants 27

Hemispherx Biopharma to Raise up to USD1 Million in Private Placement of Shares 28

Hemispherx Biopharma Raises USD0.05 Million in Private Placement of Shares 29

Hemispherx Biopharma Raises USD5 Million in Private Placement of Shares 30

Hemispherx Biopharma to Raise up to USD8 Million in Public Offering of Shares 31

Hemispherx Biopharma Announces Public Offering Of Shares For Up To USD 75 Million 33

Hemispherx Biopharma Inc-Key Competitors 34

Hemispherx Biopharma Inc-Key Employees 35

Hemispherx Biopharma Inc-Locations And Subsidiaries 36

Head Office 36

Other Locations & Subsidiaries 36

Recent Developments 37

Financial Announcements 37

Aug 15, 2018: Hemispherx announces six months ended June 30, 2018 financial results 37

May 16, 2018: Hemispherx Biopharma Reports First Quarter 2018 Financial Results and Provides Business Update 38

Apr 02, 2018: Hemispherx Biopharma Announced Financial Results for the Year Ended December 31, 2017 39

Nov 15, 2017: Hemispherx Biopharma Announces Corporate Progress and Financial Results for the Nine Months Ended September 30, 2017 40

Aug 15, 2017: Hemispherx Biopharma Announces Corporate Progress and Financial Results for the Six Months Ended June 30, 2017 41

May 15, 2017: Hemispherx Biopharma Q1 net loss increases 42

Mar 31, 2017: Hemispherx Biopharma Announces Financial Results for the Year Ended December 31, 2016 43

Corporate Communications 44

May 31, 2017: Hemispherx Biopharma appoints new deputy chief medical officer 44

Product News 45

12/20/2017: Hemispherx Successfully Completes Commercial Scale Demonstration Batch of Ampligen at Contract Manufacturer 45

09/18/2018: Hemispherx to Distribute Second Lot of Ampligen for use in Multiple Indications in Argentina, the United States and Europe 46

08/28/2018: Hemispherx Releases Recently Manufactured Ampligen for Pancreatic Cancer Early Access Program in the Netherlands to Fill Stock Order 47

08/24/2018: Hemispherx to present at the 20th annual Rodman & Renshaw Global Investment Conference 48

08/08/2017: Hemispherx Biopharma Announces Collaboration with Millions Missing Canada to Bring Medication to Canadians for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome 49

07/03/2018: Hemispherx Notes the Importance of Immunizations During Upcoming National Immunization Awareness Month and Potential of Ampligen in Influenza Vaccine Strategies 50

06/15/2018: Hemispherx Releases First 8,500 Vial Lot of Ampligen to Supply Expanded Access Programs in the United States, Europe and Canada for ME/CFS and Pancreatic Cancer and Announces Successful Finish of Second Commercial Size Lot 51

06/05/2018: Hemispherx Announces New Data Showing Ampligen's Positive Role in Reprograming Tumor Microenvironment 52

05/31/2018: Hemispherx Biopharma and Roswell Park Plan Phase I/II Study of Ampligen Plus Checkpoint Inhibitors 53

05/31/2017: Hemispherx Biopharma Enhances Ampligen Manufacturing and Scientific Capabilities 54

05/31/2017: Hemispherx Biopharma Repurposes Ampligen in Immuno-Oncology 55

05/15/2017: Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2017 56

04/17/2018: Hemispherx Successfully Completes Production of More Than 8,500 Vials of Ampligen for Commercial Sales and Expanded Clinical Programs 57

04/04/2018: Hemispherx Expands Ampligen Early Access Programme to Canada to Treat ME/CFS Patients 58

03/06/2017: Hemispherx Biopharma Meets Ampligen Sales Milestone in the 1st Quarter of 2017 59

03/05/2018: Hemispherx to Present Alferon N Injection at the 30th Annual ROTH Conference 60

03/05/2018: Hemispherx to Present Ampligen at the 30th Annual ROTH Conference 61

02/26/2018: Hemispherx To Supply Ampligen for Pancreatic Cancer Patients in Canada Under Special Access Program 62

01/26/2018: Hemispherx Announces Presentation on the Potential Role of Ampligen as an Immune System Amplifier Improving Seasonal Flu Vaccine Cross-Protection 63

01/26/2017: Hemispherx Announces First Shipment of Newly Manufactured Rintatolimod (Ampligen) for Sale to Early Access Program in Europe 64

01/25/2018: Hemispherx Announces Data Presentation on the Potential for Ampligen to Improve Cancer Outcomes with Checkpoint Inhibitors 65

01/23/2018: Hemispherx Comments on USD 500+ Million Market Opportunity for Ampligen, the Only Late Stage ME/CFS Candidate in the U.S. 66

01/17/2018: Hemispherx Enters into Sale/Leaseback Agreement for NJ Development and Production Facility 67

01/11/2018: Hemispherx Enhances Manufacturing Efficiency of Ampligen 68

01/11/2017: Hemispherx Biopharma Announces Extension of Rintatolimod European Early Access Program (EAP) to Pancreatic Cancer Patients 69

Product Approvals 70

Jun 27, 2018: Hemispherx Opens FDA-Approved Reimbursement Based Expanded Access Treatment Program for ME/CFS to New Enrollees at Approved Clinical Sites in Nevada and North Carolina 70

Clinical Trials 71

Jul 09, 2018: Hemispherx Files Positive Safety Report on Intranasal Use of Ampligen in Combination with FluMist Influenza Vaccine 71

Jan 31, 2018: Hemispherx's Ampligen Highlighted in Review of Role of TLR3 Agonist Support for Universal Flu Immunization Development Programs 72

Jan 09, 2018: Hemispherx Announces Presentation of New-Found Properties of Ampligen at Immuno-Oncology Frontiers Conference 73

Aug 14, 2017: Hemispherx Human Safety Study of Intranasal Ampligen with Influenza Vaccine Shows Ampligen was Generally Well-Tolerated 74

Jul 10, 2017: Hemispherx Updates Status of Immuno-Oncology Program in Pancreatic Cancer 75

Other Significant Developments 76

Dec 19, 2017: Hemispherx Highlights Year-To-Date Progress, Outlines Key Objectives 76

Appendix 78

Methodology 78

About GlobalData 78

Contact Us 78

Disclaimer 78


List Of Figure

List of Figures

Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Hemispherx Biopharma Inc, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Hemispherx Biopharma Inc, Deals By Therapy Area, 2012 to YTD 2018 10

Hemispherx Biopharma Inc, Medical Devices Deals, 2012 to YTD 2018 11

Hemispherx Biopharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Hemispherx Biopharma Enters into Clinical Trial Agreement with Roswell Park 14

Hemispherx Biopharma and Roswell Park Enter into Collaboration Agreement 15

Hemispherx Biopharma Enters into Agreement with University of Nebraska Medical 16

Hemispherx Biopharma Enters into Distribution Agreement with GP Pharm for Ampligen 17

Scientific Products Pharma Enters into Agreement with Hemispherx Biopharma 18

myTomorrows Enters into Agreement with Hemispherx Biopharma 19

Hemispherx Biopharma Amends Agreement with myTomorrows 20

Hemispherx Biopharma Enters into Licensing Agreement with Emerge Health 21

Hemispherx Biopharma Enters into Licensing Agreement with Emerge Health 22

Hemispherx Biopharma Plans to Raise up to USD75 Million in Public Offering of Securities 23

Hemispherx Biopharma to Raise USD2.6 Million in Private Placement of Shares 24

Hemispherx Biopharma to Raise USD0.5 Million in Private Placement of Shares 25

Hemispherx Biopharma Plans to Raise USD1.6 Million in Public Offering of Shares 26

Hemispherx Biopharma Plans to Raise Funds through Private Placement of Shares, upon Exercise of Warrants 27

Hemispherx Biopharma to Raise up to USD1 Million in Private Placement of Shares 28

Hemispherx Biopharma Raises USD0.05 Million in Private Placement of Shares 29

Hemispherx Biopharma Raises USD5 Million in Private Placement of Shares 30

Hemispherx Biopharma to Raise up to USD8 Million in Public Offering of Shares 31

Hemispherx Biopharma Announces Public Offering Of Shares For Up To USD 75 Million 33

Hemispherx Biopharma Inc, Key Competitors 34

Hemispherx Biopharma Inc, Key Employees 35

Hemispherx Biopharma Inc, Other Locations 36

Hemispherx Biopharma Inc, Subsidiaries 36

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Hemispherx Biopharma Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.